1A) The biggest gap is species-specific clinical validation. In human nutrition, we often have decades of mechanistic, pharmacokinetic, and outcome data. In pets, we still rely too heavily on extrapolation. We need more clarity on absorption differences, microbiome interactions, metabolism, and long-term safety in dogs and cats. Pets are not small humans, and their physiology proves it every day.

1B)  Species-specific research is critical. Human data can help establish mechanistic plausibility, but it should never be the finish line. Dogs and cats process nutrients differently, have distinct gut microbiomes, and age on different biological timelines. Human data may guide ingredient selection, but pet-specific dosing, safety, and outcome data are essential for credibility.

1D) Three factors stand out: standardization, purity, and bioavailability. Pets often receive smaller doses, so batch-to-batch consistency is even more critical. Purity is critical because pets can be more sensitive to contaminants. Bioavailability is often overlooked—but if the ingredient isn’t absorbed or utilized, it doesn’t matter how good it looks on paper.

1F) At a minimum, we should expect well-designed pilot or observational studies in the target species, supported by a strong mechanistic rationale and safety data. Gold-standard, large-scale trials are ideal but not always feasible. What matters is transparent study design, relevant endpoints, and honest interpretation, not borrowed claims or over-promising.

1G) Claims around mobility, cognition, calm behavior, and gut health are often misunderstood. Consumers may interpret “supports joint health” as “fixes arthritis.” This risk is reduced through plain-language education, clearly defined benefits, and by aligning claims with observable, everyday outcomes, such as comfort, activity, or digestion, rather than with medical expectations.

1H) Variability is the biggest challenge; breed, size, age, diet, and environment all influence outcomes. These challenges can be addressed through clear inclusion criteria, standardized feeding protocols, validated scoring tools, and longer study durations. Collaboration with veterinary researchers is also essential to maintain scientific rigor.

1I) Owner-reported outcomes are valuable because they capture real-world, day-to-day changes, but they can be subjective. Veterinary assessments provide objectivity. The best studies combine validated owner questionnaires with veterinary exams, biomarkers, or functional measures to create a more complete picture.

1L) Absolutely. There’s growing interest in ingredients that support mobility, digestive efficiency, immune resilience, and cognitive function as pets live longer. Healthy aging is no longer about “fixing problems” but about maintaining quality of life earlier and longer, mirroring trends we’ve already seen in human nutrition.

4A) Credibility will be driven by science-backed ingredients, transparent sourcing, responsible claims, and education, not hype. Brands that invest in species-specific research and long-term safety data will stand out. The future belongs to companies that treat pet nutrition with the same seriousness we expect in human health.

4B) Education. Clear, honest education that explains what an ingredient does, what it doesn’t do, and why it matters. When brands stop talking over consumers and start teaching them, trust follows. In my experience, informed pet parents don’t want miracles; they want truth.